AstraZeneca Clears Final Hurdle To Seal Alexion Takeover
Completion Set For 21 July
Antitrust authorities in the UK have followed their counterparts in the EU, Japan and the US to approve the AstraZeneca and Alexion link-up, the biggest pharma M&A deal of 2020.
You may also be interested in...
The UK major’s long-acting C5 inhibitor is nearing EU approval for the debilitating rare disease as the company gears up for emerging competition and loss of exclusivity for its older drug Soliris.
Mene Pangalos talked to Scrip about the importance of cultural diversity in a lab setting, pushing the frontiers on public-private partnerships and redoubling efforts on gene editing.
AstraZeneca has bulked up its late-stage pipeline with an agreement for Ionis’s eplontersen which is in trials for two rare diseases, quelling some analysts’ fears about the scarcity of catalysts for next year.